Atlantic Union Bankshares Corp trimmed its holdings in Zoetis Inc. (NYSE:ZTS) by 1.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,992 shares of the company’s stock after selling 131 shares during the quarter. Atlantic Union Bankshares Corp’s holdings in Zoetis were worth $1,817,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of ZTS. Weiss Multi Strategy Advisers LLC acquired a new position in Zoetis during the 1st quarter worth $445,000. Creative Financial Designs Inc. ADV acquired a new position in Zoetis during the 2nd quarter valued at about $46,000. Marshall Wace LLP raised its position in shares of Zoetis by 23.7% during the 2nd quarter. Marshall Wace LLP now owns 2,114,784 shares of the company’s stock worth $289,809,000 after buying an additional 404,604 shares in the last quarter. HNP Capital LLC acquired a new stake in shares of Zoetis in the 2nd quarter worth approximately $206,000. Finally, Pinnacle Bank boosted its holdings in shares of Zoetis by 9.0% in the second quarter. Pinnacle Bank now owns 2,658 shares of the company’s stock valued at $364,000 after acquiring an additional 220 shares in the last quarter. Hedge funds and other institutional investors own 92.50% of the company’s stock.
In related news, EVP Catherine A. Knupp sold 13,000 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $158.86, for a total value of $2,065,180.00. Following the completion of the sale, the executive vice president now owns 53,368 shares of the company’s stock, valued at approximately $8,478,040.48. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Heidi C. Chen sold 1,179 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $166.23, for a total value of $195,985.17. Following the completion of the transaction, the executive vice president now owns 17,514 shares in the company, valued at approximately $2,911,352.22. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 36,009 shares of company stock worth $5,720,053. 0.17% of the stock is currently owned by corporate insiders.
Shares of ZTS stock traded up $0.56 on Friday, reaching $163.55. 1,631,047 shares of the company’s stock traded hands, compared to its average volume of 2,107,758. The company has a market capitalization of $77.71 billion, a P/E ratio of 48.53, a price-to-earnings-growth ratio of 4.54 and a beta of 0.76. Zoetis Inc. has a 12-month low of $90.14 and a 12-month high of $168.96. The company has a debt-to-equity ratio of 2.41, a quick ratio of 2.60 and a current ratio of 3.47. The business’s 50 day moving average price is $161.19 and its two-hundred day moving average price is $143.22.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.25. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.35 billion. Zoetis had a net margin of 25.50% and a return on equity of 63.89%. The firm’s revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.90 earnings per share. Research analysts predict that Zoetis Inc. will post 3.62 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Wednesday, October 21st will be paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.49%. The ex-dividend date of this dividend is Tuesday, October 20th. Zoetis’s dividend payout ratio (DPR) is currently 21.98%.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: What does it mean to hold a stock in street name?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.